Has Novo pulled a trump card on Lilly?
Novo has just thrown down a trump card in the battle to launch the first oral GLP-1 drug in Australia, announcing its weight loss pill Wegovy would be available from tomorrow, seemingly trouncing Lilly's promise made on Tuesday to have its rival product Foundayo on the market "in coming days".
To see the whole article, log in or create an account.